Back to Search
Start Over
Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials.
- Source :
-
Dermatitis : contact, atopic, occupational, drug [Dermatitis] 2023 Jul-Aug; Vol. 34 (4), pp. 308-314. Date of Electronic Publication: 2023 Feb 06. - Publication Year :
- 2023
-
Abstract
- Background: Tolerability issues including acne, nausea, and headache have been reported with Janus kinase (JAK) inhibitors for moderate-to-severe atopic dermatitis (AD). Objectives: To report outcomes of tolerability adverse events (AEs) for baricitinib, a JAK1/JAK2 inhibitor, in patients with moderate-to-severe AD. Methods: Acne, headache, and gastrointestinal AEs are reported from placebo-controlled and long-term extensions of pooled data in the baricitinib AD clinical trial program. Proportions of patients with AEs, incidence rates (IRs)/100 patient-years at risk, and median time to onset/duration of AEs were calculated. Results: In 2531 patients treated with baricitinib, most AEs were mild to moderate in severity. Headache was the most common AE of tolerability (median of 14-26 days after first dose of baricitinib, lasting ≤3 days). IRs of acne were <5 in any group lasting up to a median of 90 days with no severe AEs. Diarrhea was the most common gastrointestinal AE, lasting a median of ≤7 days. There were few study drug interruptions (n = 6) and permanent discontinuations (n = 5) for tolerability AEs. Conclusions: For the AEs of tolerability analyzed, baricitinib appears to be well tolerated. Overall, the frequency of these AEs in patients being treated for moderate-to-severe AD was low with few leading to study drug interruption or permanent discontinuation. Clinical Trial Registration number: NCT02576938; NCT03334396; NCT03334422; NCT03428100; NCT03435081; NCT03733301; NCT03334435; NCT03559270.
- Subjects :
- Humans
Sulfonamides adverse effects
Headache chemically induced
Treatment Outcome
Severity of Illness Index
Double-Blind Method
Dermatitis, Atopic drug therapy
Dermatitis, Atopic chemically induced
Acne Vulgaris drug therapy
Acne Vulgaris chemically induced
Janus Kinase Inhibitors adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 2162-5220
- Volume :
- 34
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Dermatitis : contact, atopic, occupational, drug
- Publication Type :
- Academic Journal
- Accession number :
- 36749121
- Full Text :
- https://doi.org/10.1089/derm.2022.0027